Kai-Uwe Lewandrowski^1-3,26, Abdalla Bowirrat⁴, Albert Pinhasov⁴, Alireza Sharafshah⁵, Mark S Gold⁶, Brian Fuehrlein⁷, Igor Elman^4,8, Catherine Dennen⁹, Panayotis K. Thanos¹⁰, Colin Hanna¹⁰, Daniel Sipple¹¹, David Baron¹² ,Gianni Martire¹³, Edward J Modestino¹⁴, Nicole Jafari^15,16, Foojan Zeine^17,18, Keerthy Sunder^19,20, Alexander PL Lewandrowski²¹, Rajendra D Badgaiyan^22,23, Jag Khalsa^24,25, Aryeh Pollack²², Rossano Kepler Alvim Fiorelli²⁶, Sergio Schmidt²⁷, Chynna Fliegelman^22,28, Morgan P Lorio²⁹, Milan T Makale³⁰ and Kenneth Blum^{2,4,12, 16,17,22, 26,31-33}*

¹Department of Orthopaedics, Fundación Universitaria Sanitas Bogotá D.C. Colombia
²Division of Personalized Pain Therapy Research, Center for Advanced Spine Care of Southern Arizona, Tucson, AZ.,USA
³Department of Orthopedics at Hospital Universitário Gaffree Guinle Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
⁴Department of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel.
⁵Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
⁶Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
⁷Yale University School of Medicine, Yale-New Haven Hospital, United States; Psychiatric Emergency Room, VA Connecticut, Yale University, New Haven, CT., USA
⁸Department of Psychiatry, Harvard University College of Medicine, Cambridge, MA, USA.
⁹Department of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, USA.
¹⁰Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, State University of New York at Buffalo, Buffalo, NY, USA.
¹¹Midwest Brain and Spine Institute, Roseville, MS, USA.
¹²Division of Addiction Research and Education, Center for Exercise Sports, Mental Health, Western University Health Sciences, Pomona, CA, USA.
¹³Biophysics Research in Advanced Interdisciplinary Neuroscience BRAIN at Applied Physics, NYC, NY, USA
¹⁴Department of Psychology, Curry Collage, Milton, MA.,USA
¹⁵Department of Human Development, California State University at Long Beach, Long Beach, CA., USA,
¹⁶Division of Personalized Medicine, Cross-Cultural Research and Educational Institute, San Clemente, CA., USA
¹⁷Awareness Integration Institute, San Clemente, CA, USA
¹⁸Department of Health Science, California State University at Long Beach, Long Beach, CA., USA
¹⁹Department of Psychiatry, University California, UC Riverside School of Medicine, Riverside, CA., USA
²⁰Division of Neuromodulation Research, Karma Doctors and Karma TMS, Palm Springs, CA., USA
²¹Department of Biological Sciences, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA, USA.
²²Division of Nutrigenomics and Personalized Medicne, The Blum Institute of Neurogenetics and Behavior, Austin, Tx., USA
²³ Department of Psychiatry, Texas Tech University Health Sciences School of Medicine, Midland, TX., USA
²⁴ US National Institute on Drug Abuse, NIH; Medical Consequences of Drug Abuse and Infections Branch, National Institute on Drug Abuse, NIH, Bethesda, Maryland (Volunteer)
²⁵ Microbiology, Immunology, and Tropical Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC
²⁶ Faculdade de Ciências Médicas de Três Rios (SUPREMA), Rio de Janeiro 25804-250, Brazil.
²⁷ Department of Neurology, Federal University of Rio de Janeiro (UNIRIO), University Hospital, Rua Mariz e Barros 750, Tijuca, Rio de Janeiro, RJ, Brazil.
²⁸ Department of Psychology, St. John University, Queens, NYC, NY., USA
²⁹ Advanced Orthopedics, Altamonte Springs, FL, on behalf of the International Society for the Advancement of Spine Surgery.
³⁰Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA., USA.
³¹Institute of Psychology, Eötvös Loránd University Budapest, Budapest, Hungary.
³²Department of Psychiatry, Boonshoft School of Medicine, Wright University, Dayton, OH, USA.
³³Department of Psychiatry, Human Integrated Services Unit, University of Vermont Center for Clinical and Translational Science, College of Medicine, Burlington, VT, USA

*Corresponding Author: Kenneth Blum, Division of Personalized Pain Therapy Research, Center for Advanced Spine Care of Southern Arizona, Tucson, AZ.,USA.

Received: March 21, 2025; Published: April 28, 2025

Abstract

In spite of the ongoing exquisite work of a multitude of researchers worldwide including governmental institutions like the National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and for example in the United States the FDA Medication Assisted Therapy (MAT) embracing Opioid Replacement Therapy (ORT) in 2022, 111,000 people prematurely died from opioid induced overdose. It is estimated that if treatment stays as usual by 2025 the death rate will increase to 165,00.Therefore, we are encouraging the scientific and clinical community to at least consider our “out of the box” thinking whereby we are proposing a new paradigm shift involving the “ dopaminergic homeostatic modeling approach and Genetic screening to early identify preaddiction. In this novel approach following detoxification from for example powerful opioids, the patient is administered the validated RDSQ29 to access potential psychological profiling of Reward Deficiency Syndrome (RDS); obtain a cheek cell sample of the patient and perform genetic screening utilizing the Genetic Addiction Risk Severity (GARS); analyze mRNA to identify specific protein deficits/surfeits based on the measured reward genes involved in the Brain Reward Cascade (BRC); produce a customized pro-dopamine regulator (KB220) guided by GARS resulting polymorphisms; objectively employ the mRNA profiling assessment every week during the treatment phase to determine improvement; each treatment program could add on at their choice, for example, cognitive behavioral therapy, brain spotting, trauma therapy, electrotherapy (h-wave device to reduce pain, subluxation repair etc.) mindfulness, exercise, neuromodulation (PrTMS) amongst other modalities. The utilization of this model could prove beneficial to both substance and non-substance behavioral addictions (e. g. gaming). WC261

 Keywords: Behavioural Addictions; Dopamine, Neurotransmitters; GARS; Preaddiction; MAT; Harm Avoidance

References

1. World Health Organization: International statistical classification of diseases and related health problems (11^th Revision) (2022).
2. Brand M., et al. “Which conditions should be considered as disorders in the International Classification of Diseases (ICD-11) designation of “other specified disorders due to addictive behaviors?” Journal of Behavioral Addictions 2 (2020): 150-159.
3. Müller A., et al. “Buying-shopping disorder-is there enough evidence to support its inclusion in ICD-11?” CNS Spectrums (2019): 1-6.
4. Bőthe B., et al. “Contradicting ncotargetion, nomenclature, and diagnostic criteria of compulsive sexual behavior disorder (CSBD) and future directions •: commentary to the debate: “Behavioral addictions in the ICD-11”. Journal of Behavioral Addictions2 (2022): 204-209.
5. Gullo MJ., et al. “Criteria for the establishment of a new behavioural addiction •: commentary to the debate: “Behavioral addictions in the ICD-11”. Journal of Behavioral Addictions2 (2022): 191-198.
6. Blum K., et al. “Evidence for the DRD2Gene as a Determinant of Reward Deficiency Syndrome (RDS)”. Clinical and Experimental Phycology4 (2023): 8-11.
7. Blum K., et al. “The D2 dopamine receptor gene is a determinant of reward deficiency syndrome”. The Journal of the Royal Society of Medicine 7 (1999): 396-400.
8. Musto DF. “Historical perspectives. In ‘‘Substance Abuse: A Comprehensive Textbook’ ( J. H. Lowinson, P. Ruiz, R. B. Millman, J. C. Langrod, Eds.), 3^rd edition (1997).
9. McLellan AT., et al. “Preaddiction-A Missing Concept for Treating Substance Use Disorders”. JAMA Psychiatry 8 (2022): 749-751.
10. Hamilton PJ and Nestler EJ. “Epigenetics and addiction”. Current Opinion in Neurobiology 59 (2019): 128-136.
11. Oades RD and Halliday GM. “Ventral tegmental (A10) system: Neurobiology. 1. Anatomy and connectivity”. Brain Research 434 (1987): 117-165.
12. Dresp-Langley B. “From Reward to Anhedonia-Dopamine Function in the Global Mental Health Context”. Biomedicines9 (2023): 2469.
13. Buck SA., et al. “Roles of dopamine and glutamate co-release in the nucleus accumbens in mediating the actions of drugs of abuse”. FEBS Journal5 (2019): 1462-1474.
14. Thanos PK., et al. “Dopamine D2 gene expression interacts with environmental enrichment to impact lifespan and behavior”. Oncotarget15 (2016): 19111-19123.v
15. Badgaiyan RD., et al. “Attenuated Tonic and Enhanced Phasic Release of Dopamine in Attention Deficit Hyperactivity Disorder”. PloS One 9 (2015): e0137326.
16. Melis M., et al. “The dopamine hypothesis of drug addiction: hypodopaminergic state”. International Review of Neurobiology 63 (2005): 101-154.
17. Fried L., et al. “Hypodopaminergia and “Precision Behavioral Management” (PBM): It is a Generational Family Affair”. Current Pharmaceutical Biotechnology6 (2020): 528-541.
18. Dackis CA and Gold MS. “New concepts in cocaine addiction: the dopamine depletion hypothesis”. Neuroscience and Biobehavioral Reviews3 (1985): 469-477.
19. Gondré-Lewis MC., et al. “Frequency of the Dopamine Receptor D3 (rs6280) vs. Opioid Receptor µ1 (rs1799971) Polymorphic Risk Alleles in Patients with Opioid Use Disorder: A Preponderance of Dopaminergic Mechanisms?” Biomedicines4 (2009): 870.
20. Blum K., et al. “Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis”. Frontiers in Psychiatry 12 (2021):
21. Diana M. “The dopamine hypothesis of drug addiction and its potential therapeutic value”. Frontiers in Psychiatry 2 (2011):
22. Sanna F., et al. “Involvement of dopamine in the differences in sexual behaviour between Roman high and low avoidance rats: an intracerebral microdialysis study”. Behavioural Brain Research 281 (2015): 177-186.
23. Zhang R., et al. “Dopamine D1 and D2 receptors are distinctly associated with rest-activity rhythms and drug reward”. Journal of Clinical Investigation18 (2021): e149722.
24. Willuhn I., et al. “Excessive cocaine uses results from decreased phasic dopamine signaling in the striatum”. Nature Neuroscience5 (2014): 704-709.
25. Jaber M., et al. “Dopamine receptors and brain function”. Neuropharmacology11 (1996): 1503-1519.
26. Berridge KC and Robinson TE. “Liking, wanting, and the incentive-sensitization theory of addiction”. American Psychologist8 (1996): 670-679.
27. Blum K., et al. “Liking” and “wanting” linked to Reward Deficiency Syndrome (RDS): hypothesizing differential responsivity in brain reward circuitry”. Current Pharmaceutical Design1 (2012): 113-118.
28. File D., et al. “The Role of Impulsivity and Reward Deficiency in “Liking” and “Wanting” of Potentially Problematic Behaviors and Substance Uses”. Frontiers in Psychiatry 13 (2022):
29. Olive MF., et al. “Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release”. European Journal of Pharmacology 1-2 (2022): 55-61.
30. Sorge RE and Stewart J. “The effects of long-term chronic buprenorphine treatment on the locomotor and nucleus accumbens dopamine response to acute heroin and cocaine in rats”. Pharmacology Biochemistry and Behavior 2 (2006): 300-305.
31. Hill E., et al. “Long term Suboxone™ emotional reactivity as measured by automatic detection in speech”. PloS One 7 (2013): e69043.
32. Blum K., et al. “Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity cause anti-reward and relapse potential?” Molecular Neurobiology3 (2011): 250-268.
33. Elman I and Borsook D. “The failing cascade: Comorbid post-traumatic stress- and opioid use disorders”. Neuroscience and Biobehavioral Reviews 103 (2019): 374-383.
34. Gold MS., et al. “Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?” Journal of the Neurological Sciences 418 (2020):
35. Goldstein N., et al. “Specificity of Varenicline in Blocking Mesolimbic Circuit Activation to Natural and Drug Rewards”. Neuroscience 483 (2022): 40-51.
36. Dowell D., et al. “CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022”. MMWR Recommendations and Reports3 (2022): 1-95.
37. Blum K and Kozlowski GP. “Ethanol and neuromodulator interaction: a cascade model of reward. In: Ollat H, Parvez S, Parvez H, editors”. Alcohol and Behavior.VSP Press Utrecht; The Netherlands (1990): 131-149. 
38. Wise RA and Bozarth MA. “Brain reward circuitry: four circuit elements “wired” in apparent series”. Brain Research Bulletin 2 (1984): 203-208.
39. Gardner EL. “Addiction and brain reward and antireward pathways”. Advances in Psychosomatic Medicine 30 (2011): 22-60.
40. Kotyuk E., et al. “Co-occurrences of substance use and other potentially addictive behaviors: Epidemiological results from the Psychological and Genetic Factors of the Addictive Behaviors (PGA) Study”. Journal of Behavioral Addictions2 (2020): 272-288.
41. Norman TR and Olver JS. “A challenge to the dopamine orthodoxy in schizophrenia?” Australian and New Zealand Journal of Psychiatry 9 (2023): 1198-1199.
42. Gold MS., et al. “Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti- reward systems”. Frontiers in Bioscience-Scholar 2 (2018): 309-325.
43. Blum K., et al. “Hypothesizing that a Pro-Dopaminergic Regulator (KB220z^™Liquid Variant) can Induce “Dopamine Homeostasis” and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence”. Clinical Medical Reviews and Case Reports8 (2016): 125.
44. Kótyuk E., et al. “Development and validation of the Reward Deficiency Syndrome Questionnaire (RDSQ-29)”. The Journal of Psychopharmacology 3 (2022): 409-422.
45. Blum K., et al. “Evidence for the DRD2Gene as a Determinant of Reward Deficiency Syndrome (RDS)”. Clinical and experimental Phycology Journals 4 (2023): 8-11.
46. Blum K., et al. “Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case-Control Subjects”. Journal of Personalized Medicine 9 (2022): 1385.
47. Blum K., et al. “The benefits of customized DNA directed nutrition to balance the brain reward circuitry and reduce addictive behaviors”. Precious Medical (Bangalore)1 (2016): 18-33.
48. Blum K., et al. “A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing “Precision Behavioral Management”. Psychology Research and Behavior Management 14 (2021): 2115-2134.
49. Tapocik JD., et al. “Neuroplasticity, axonal guidance and micro-RNA genes are associated with morphine self-administration behavior”. Addiction Biology 18.3 (2013): 480-495.
50. Bertran-Gonzalez J., et al. “What is the degree of segregation between striatonigral and striatopallidal projections?” Frontiers in Neuroanatomy 4 (2010): 136.
51. Hikida T., et al. “Pathway-specific modulation of nucleus accumbens in reward and aversive behavior via selective transmitter receptors”. Proceedings of the National Academy of Sciences of the United States of America 1 (2013): 342-347.
52. Hikida T., et al. “Distinct roles of synaptic transmission in direct and indirect striatal pathways to reward and aversive behavior”. Neuron6 (2010): 896-907.
53. Noble EP., et al. “Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism”. Archives of General Psychiatry 7 (1991): 648-654.
54. Blum K., et al. “Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD)”. Journal of Systems and Integrative Neuroscience (2019):
55. Downs BW., et al. “Death by Opioids: Are there non-addictive scientific solutions?” Journal of Systems and Integrative Neuroscience 5 (2019):
56. Chen TJ., et al. “Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy”. Medical Hypotheses 3 (2004): 538-548.
57. Blum K., et al. “Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual”. Journal of Systems and Integrative Neuroscience 7 (2020):
58. Dennen AC., et al. “How to Combat the Global Opioid Crisis”. CPQ Neurology and Psychology4 (2023): 93.
59. Reiff CM., et al. “McDonald WM; the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research. Psychedelics and Psychedelic-Assisted Psychotherapy”. The American Journal of Psychiatry5 (2020): 391-410.
60. Sakashita Y., et al. “Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats”. Biological and Pharmaceutical Bulletin1 (2015): 134-138.
61. Ray LA., et al. “Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders: A Systematic Review and Meta-analysis”. JAMA Network Open 6 (2020): e208279.
62. Zeine F. “Awareness integration: a new therapeutic model”. International Journal of Emergency Mental Health 2 (2014): 278-283.
63. Makale MT., et al. “Preliminary Observations of Personalized Repetitive Magnetic Stimulation (PrTMS) Guided by EEG Spectra for Concussion”. Brain Science8 (2023): 1179.
64. Makale MT., et al. “Personalized repetitive transcranial magnetic stimulation (PrTMS®) for post-traumatic stress disorder (PTSD) in military combat veterans”. Heliyon8 (2023): e18943.v
65. Bajaj A., et al. “Positive Clinical Outcomes for Severe Reported Pain Using Robust Non-Addictive Home Electrotherapy-A Case-Series”. Journal of Personalized Medicine 2 (2023): 336.
66. Preuss CV., et al. “Prescription of Controlled Substances: Benefits and Risks. 2023 Apr 29. In: StatPearls Internet. Treasure Island (FL): StatPearls Publishing (2023).
67. Blum K., et al. “Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?” Substance Use and Misuse 12 (2016): 1674-1679.
68. Zaaijer ER., et al. “Acceptability of Extended-Release Naltrexone by Heroin-Dependent Patients and Addiction Treatment Providers in the Netherlands”. Substance Use and Misuse 14 (2016): 1905-1911.
69. Top of Form
70. Blum K., et al. “Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual”. Journal of Systems and Integrative Neuroscience 7 (2020).
71. Kenneth Blum., et al. “Neurogenetics and gene therapy for reward deficiency syndrome: are we going to the Promised Land?” Expert Opinion on Biological Therapy 7 (2015): 973-985.
72. Thanos PK., et al. “Overexpression of dopamine D2 receptors reduces alcohol self-administration”. Journal of Neurochemistry 5 (2001): 1094-1103.
73. Thanos PK., et al. “Dopamine D2R DNA transfer in dopamine D2 receptor-deficient mice: effects on ethanol drinking”. Life Science2 (2005): 130-139.
74. Thanos PK., et al. “Volkow ND. D2R DNA transfer into the nucleus accumbens attenuates cocaine self-administration in rats”. Synapse7 (2008): 481-486.
75. Davis LM., et al. “Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesity”. Neuroendocrinology2 (2009): 152-162.
76. Perreault B., et al. “Effects of Exercise on Testosterone and Implications of Drug Abuse: A Review”. Clinical Neuropharmacology3 (2023): 112-122.
77. Robison LS., et al. “Exercise Reduces Dopamine D1R and Increases D2R in Rats: Implications for Addiction”. Medicine and Science in Sports and Exercise8 (2018): 1596-1602.
78. Swenson S., et al. “The therapeutic potential of exercise for neuropsychiatric diseases: A review”. Journal of the Neurological Sciences 412 (2020):
79. Rahman N., et al. “Chronic aerobic exercise: Autoradiographic assessment of GABA (a) and mu-opioid receptor binding in adult rats”. Pharmacology Biochemistry and Behavior 196 (2020):
80. Hanna C., et al. “Exercise Modulates Brain Glucose Utilization Response to Acute Cocaine”. Journal of Personalized Medicine 12 (2022): 1976.
81. Hanna C., et al. “Brain Mapping the Effects of Chronic Aerobic Exercise in the Rat Brain Using FDG PET”. Journal of Personalized Medicine 6 (2022): 860.
82. Swenson S., et al. “Chronic aerobic exercise: Lack of effect on brain CB1 receptor levels in adult rats”. Life Science 230 (2019): 84-88.
83. Delis F., et al. “Chronic mild stress increases alcohol intake in mice with low dopamine D2 receptor levels”. Behavioral Neuroscience1 (2013): 95-105.
84. Cordeiro LMS, Rabelo PCR, Moraes MM, Teixeira-Coelho F, Coimbra CC, Wanner SP, Soares DD. ., et al. “ Physical exercise-induced fatigue: the role of serotonergic and dopaminergic systems”. The Brazilian Journal of Medical and Biological Research 12 (2017): e6432.
85. Harber VJ and Sutton JR. “Endorphins and exercise”. Sports Medicine2 (1984): 154-171.
86. Baraniuk JN., et al. “Exercise modifies glutamate and other metabolic biomarkers in cerebrospinal fluid from Gulf War Illness and Myalgic encephalomyelitis/Chronic Fatigue Syndrome”. PLoS One1 (2021): e0244116.
87. Bastioli G., et al. “Voluntary Exercise Boosts Striatal Dopamine Release: Evidence for the Necessary and Sufficient Role of BDNF”. Journal of Neuroscience23 (2022): 4725-4736.
88. Conlay LA., et al. “Exercise and neuromodulators: choline and acetylcholine in marathon runners”. International Journal of Sports Medicine 1 (1992): S141-142.
89. Sandsdal RM., et al. “Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial”. Cardiovascular Diabetology 1 (2023): 41.
90. Córdoba-Grueso WS., et al. “The association between exercise and prescription opioid misuse: A scoping review”. Experimental and Clinical Psychopharmacology2 (2024): 140-149.
91. Wu J., et al. “Analysis of physical activity and prescription opioid use among US adults: a cross-sectional study”. BMC Public Health1 (2024): 698.
92. Furulund E., et al. “TLAS4LAR study group. Integrated exercise program in opioid agonist therapy clinics and effect on psychological distress: study protocol for a randomized controlled trial (BAReAktiv)”. Trials 1 (2024): 155.
93. Li G., et al. “Association between physical activity and depression in adult prescription opioid users: A cross-sectional analysis based on NHANES 2007-2018”. General Hospital Psychiatry 89 (2024): 1-7.
94. Brown JM., et al. “Delay discounting is associated with addiction and mental health measures while controlling health behaviors and health barriers in a large US sample”. Addictive Behaviors Reports 19 (2024):
95. Dong YG., et al. “Treadmill exercise training inhibits morphine CPP by reversing morphine effects on GABA neurotransmission in D2-MSNs of the accumbens-pallidal pathway in male mice”. Neuropsychopharmacology11 (2024): 1700-1710.
96. Cui Y., et al. “Joint effects of prescription opioid use and physical activity on depressive symptoms”. Public Health 236 (2024): 430-435.
97. Furulund E., et al. “A qualitative study of experiences with physical activity among people receiving opioid agonist therapy”. Substance Abuse Treatment, Prevention, and Policy1 (2024): 26.
98. Does MB., et al. “A patient activation intervention in primary care for patients with chronic pain on long term opioid therapy: results from a randomized control trial”. BMC Health Services Research1 (20124): 112.
99. Sharafshah A., et al. “Synergistic Epistasis and Systems Biology Approaches to Uncover a Pharmacogenomic Map Linked to Pain, Anti-Inflammatory and Immunomodulating Agents (PAIma) in a Healthy Cohort”. Cell Molecular Neurobiology1 (2024): 74.
100. Rossi R., et al. “Stepped Care for Patients to Optimize Whole Recovery (SC-POWR): An Effectiveness Trial Evaluating a Stepped Care Model for Individuals With Opioid Use Disorder and Chronic Pain”. The Journal of Substance Use and Addiction Treatment1 (2025): 146-154.
101. Winget V., et al. “Yoga and Pilates for those with chronic pain: A pilot study among women in substance use rehabilitation”. The Journal of Bodywork and Movement Therapies 40 (2024): 1544-1547.

Citation

Citation: Kenneth Blum., et al. “Dopaminergic Homeostatic Therapy (DHT™) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS®) Screening". Acta Scientific Neurology 8.4 (2025): 70-88.

Copyright

Copyright: © 2025 Kenneth Blum., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.